Equillium (EQ) Stock: Buy, Sell, or Hold?
EQ - Equillium, Inc. Common Stock
$1.96
0.07 (3.70%)
▲
5d:
-7.11%
30d:
-15.88%
90d:
-35.74%
HOLD
MODERATE Confidence
Analysis Updated: Sep 18, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When EQ Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: EQ shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: EQ shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: EQ is currently trading at $1.96, which is considered oversold relative to its 30-day fair value range of $2.06 to $2.40.
Technical Outlook: Technically, EQ is in a strong uptrend. Immediate support is located at $1.80, while resistance sits at $2.69. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $8.56 (+352.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, EQ is in a strong uptrend. Immediate support is located at $1.80, while resistance sits at $2.69. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $8.56 (+352.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.06 -
$2.40
Company Quality Score
55/100
(HOLD)
Options IV Signal
100th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
69.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Options expensive (IV 100th percentile)
- NEUTRAL: Mixed technical signals (50/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.7%)
- BULLISH: Trading 352.7% below Wall St target ($8.56)
- NEUTRAL: Bottoming setup forming (50/100) — watch for confirmation
- CAUTION: 5-day price weakness (-7.1%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$2.06 -
$2.40
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.57
(29.2%)
Support & Resistance Levels
Support Level
$1.80
Resistance Level
$2.69
Current Trend
Strong Uptrend
Technical data as of
Sep 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.07
Wall Street Target
$8.56
(+352.7%)
Revenue Growth (YoY)
-52.3%
Share & Embed Analysis
Last updated: September 18, 2026 2:41 PM ET
Data refreshes hourly during market hours. Next update: 3:41 PM
Data refreshes hourly during market hours. Next update: 3:41 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EQ showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 63 BUY |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 33 SELL |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$569 | 49 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$314 | 51 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$49 | 67 BUY |